Bristol-Myers Story

BMY -- USA Stock

USD 59.34 1.41 2.32%

Macroaxis Story

Bristol Myers Book Value per Share is fairly stable at the moment as compared to the past year. Bristol Myers reported Book Value per Share of 36.42 in 2020. Dividend Yield is likely to rise to 0.0248 in 2021, whereas Net Income Per Employee is likely to drop slightly above 100.7 K in 2021. If you are looking to grow your portfolio over time, you may want to break down all of the essential basic indicators of your selected equities before buying their shares. In this article, we will break down Bristol Myers. We will analyze why Bristol Myers investors may still consider a stake in the business. We currently estimate Bristol Myers as undervalued. The real value is approaching 67.92 per share.

Published over three weeks ago

View all stories for Bristol-Myers Squibb | View All Stories

Will Bristol Myers (NYSE:BMY) basic indicators remain weak in March?

Macroaxis provides unbiased investment recommendation on Bristol Myers Squibb that should be used to complement current analysts and expert consensus on Bristol Myers Squibb. Our trade advice engine determines the company's potential to grow exclusively from the perspective of an investors' current risk tolerance and investing horizon.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Bristol-Myers Squibb income statement, its balance sheet, and the statement of cash flows. Potential Bristol-Myers Squibb investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bristol-Myers Squibb investors may use each financial statement separately, they are all related. The changes in Bristol-Myers Squibb's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol-Myers Squibb's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Bristol-Myers Squibb fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Bristol-Myers Squibb performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Bristol-Myers Squibb shares is the value that is considered the true value of the share. If the intrinsic value Bristol-Myers is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Bristol-Myers Squibb.

Please read more on our fundamental analysis page.

What is Bristol-Myers Asset Breakdown?

Bristol-Myers Squibb reports assets on its Balance Sheet. It represents the amount of Bristol-Myers resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Bristol-Myers volatility, please check the breakdown of all its fundamentals

Are Bristol-Myers Squibb Earnings Expected to grow?

The future earnings power of Bristol-Myers Squibb involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Bristol-Myers Squibb factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Bristol-Myers Squibb stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Bristol-Myers expected earnings.

And What about dividends?

A dividend is the distribution of a portion of Bristol-Myers Squibb earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Bristol-Myers Squibb dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. Bristol-Myers one year expected dividend income is about $0.86 per share.

Payment of Dividends and Other Cash Distributions is likely to drop to about (4.4 B) in 2021. Dividend Yield is likely to drop to 0.0323 in 2021.

	Last Reported	Projected for 2021
Payment of Dividends and Other Cash Distributions	-4.1 B	-4.4 B
Dividend Yield	0.037	0.0323
Dividends per Basic Common Share	2.29	2.08

Investing in dividend-paying stocks, such as Bristol-Myers Squibb is one of the few strategies that are good for long-term investment. Ex-dividend dates are significant because investors in Bristol-Myers Squibb must own a stock before its ex-dividend date to receive its next dividend.

This type of analysis is very useful when you want to generate a past dividend schedule and payout information for Bristol-Myers Squibb. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.

It is good to see analyst projects for Bristol-Myers Squibb, but it might be worth checking our own buy vs. sell analysis

Bristol-Myers Squibb Gross Profit

Bristol-Myers Squibb Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Bristol-Myers Squibb previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Bristol-Myers Squibb Gross Profit growth over the last 10 years.

Please check Gross Profit in more details.

Exercise or conversion by Rupert Vessey of 23349 shares of Bristol-Myers Squibb subject to Rule 16b-3

Legal trades by Bristol-Myers Squibb insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Bristol-Myers insider trading alert for exercise of restricted stock units by Rupert Vessey, EVP Research & Early Dev., on 3rd of March 2021. This event was filed by Bristol Myers Squibb Co with SEC on 2021-03-03. Statement of changes in beneficial ownership - SEC Form 4. Rupert Vessey currently serves as executive vice president research and early development member of the leadership team of Bristol-Myers Squibb [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down

Institutional investor usually refers to an organization that invests money in Bristol Myers on behalf of clients or other money managers. Buying and selling of large positions of Bristol Myers stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Bristol Myers stock. Let's take a look at how the ownership of Bristol is distributed among investors.

Ownership Allocation

Bristol Myers Squibb retains a total of 2.26 Billion outstanding shares. The majority of Bristol Myers Squibb outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bristol Myers Squibb to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bristol Myers. Please pay attention to any change in the institutional holdings of Bristol Myers Squibb as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors

24.13%

Institutions

75.79%

	Retail Investors	24.13
	Insiders	0.08
	Institutions	75.79

	2018	2019	2020	2021 (projected)
Consolidated Income	4.95 B	3.46 B	3.11 B	3 B
Direct Expenses	6.55 B	8.08 B	7.27 B	6.08 B

Consolidated Income Direct Expenses

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bristol Myers has an asset utilization ratio of 124.1 percent. This suggests that the company is making $1.24 for each dollar of assets. An increasing asset utilization means that Bristol Myers Squibb is more efficient with each dollar of assets it utilizes for everyday operations.

Assets Non Current

124.8 B

Goodwill

107.3 B

Current Assets	26.9 Billion	10.37
Assets Non Current	124.81 Billion	48.11
Goodwill	107.27 Billion	41.35
Tax Assets	471.08 Million	0.18

How will Bristol investors react to the next slide?

Current Risk Adjusted Performance is up to 0.08. Price may slide again. Bristol Myers Squibb has relatively low volatility with skewness of 0.93 and kurtosis of 3.99. However, we advise all investors to independently investigate Bristol Myers Squibb to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

The Current Takeaway on Bristol Myers Investment

While few other entities in the drug manufacturers?general industry are either recovering or due for a correction, Bristol Myers may not be performing as strong as the other in terms of long-term growth potentials. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Bristol Myers.

About Contributor

Gabriel Shpitalnik is a Member of Macroaxs Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Bristol-Myers Squibb. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC